{"id":"NCT04973449","sponsor":"AstraZeneca","briefTitle":"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","officialTitle":"A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-06-27","primaryCompletion":"2022-02-04","completion":"2022-08-02","firstPosted":"2021-07-22","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":2843,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19","SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"AZD1222","otherNames":[]},{"type":"BIOLOGICAL","name":"AZD2816","otherNames":[]}],"arms":[{"label":"Primary Vaccination Cohort:- AZD1222 (4)","type":"EXPERIMENTAL"},{"label":"Primary Vaccination Cohort:- AZD2816 (4)","type":"EXPERIMENTAL"},{"label":"Primary Vaccination Cohort:- AZD1222 + AZD2816 (4)","type":"EXPERIMENTAL"},{"label":"Primary Vaccination Cohort:- AZD2816 (12)","type":"EXPERIMENTAL"},{"label":"Booster Cohort:- AZD1222:AZD1222","type":"EXPERIMENTAL"},{"label":"Booster Cohort:- AZD1222:AZD2816","type":"EXPERIMENTAL"},{"label":"Booster Cohort:- mRNA:AZD1222","type":"EXPERIMENTAL"},{"label":"Booster Cohort:- mRNA:AZD2816","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).","primaryOutcome":{"measure":"Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster Cohorts:-AZD1222:AZD2816, and mRNA:AZD2816","timeFrame":"During the 7-day follow-up period after vaccination (vaccines administered on Days 1 and 29 [only for primary vaccination cohort])","effectByArm":[{"arm":"Primary Vaccination Cohort:- AZD2816 (4)","deltaMin":319,"sd":null},{"arm":"Booster Cohort:- AZD1222:AZD2816","deltaMin":275,"sd":null},{"arm":"Booster Cohort:- mRNA:AZD2816","deltaMin":277,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["Brazil","Poland","South Africa","United Kingdom"]},"refs":{"pmids":["38878794","37783221"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7220C00001&amp;attachmentIdentifier=0a3a6e16-16b7-4123-a7e4-f72724ff24f2&amp;fileName=d7220c00001-sap-Redacted-27Jan23.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7220C00001&amp;attachmentIdentifier=2702b48f-fd68-4497-ab85-0d17d2b22b0f&amp;fileName=d7220c00001-16-1-01-protocol-and-protocol-amendments-final.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7220C00001&amp;attachmentIdentifier=e750a312-5649-468d-b51e-8baf87ab2ae1&amp;fileName=d7220c00001-final-synopsis-Redacted_PDFA.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":409},"commonTop":["COVID-19"]}}